Japan's Santen files EMA marketing authorization for intravitreal sirolimus eye drug

SINGAPORE--Japan's Santen Pharmaceutical Co. said the European Medicines Agency (EMA) has accepted the company's Marketing Authorization Application for intravitreal sirolimus, an investigational mTOR inhibitor, for the treatment of noninfectious uveitis of the posterior segment, a leading cause of blindness.

The submission to the EMA was supported by a pivotal Phase III study.

- read the release